Journal
SENSORS AND ACTUATORS B-CHEMICAL
Volume 263, Issue -, Pages 668-675Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.snb.2018.02.015
Keywords
Centrifugal microfluidics; Prostate cancer; Point-of-care; Centrifugal flow control; Multiplexing; Multi-marker panel
Funding
- European Commission FP7 Programme through the Marie Curie Initial Training Network PROSENSE [317420]
- Biomedical Diagnostics Institute (BDI) through the Science Foundation Ireland (SFI) [10/CE/B1821 SFI-TIDA 13/TIDA/B2692, SFI-TIDA 14/TIDA/2264]
Ask authors/readers for more resources
Early diagnosis and prognosis of prostate cancer (PCa) is increasingly moving towards evaluations based on a strategic combination of biomarkers. The ability to parallelize multi-parameter detection on the same device is hence considered as a substantial improvement compared to conventional, single-marker methods such as total prostate-specific antigen (t-PSA). We demonstrate full rotational control of a centrifugal microfluidic system which is geared to automate multi-step/multi-reagent protocols underlying PCa detection based on a multi-marker panel on a widely autonomous, cost-efficient and rugged point of-care instrument. Such comprehensive fluidic integration is enabled by a novel type of dissolvable-film (DF) valve which significantly enhances the definition of its critical release frequency by a factor of more than 3 (average spread of +/- 1.8 Hz), and thus substantially enhances process reliability and integration density on our Lab-on-a-Disc (LoaD) platform. This siphon-based centrifugo-pneumatic flow control scheme can be attuned merely by temporal modulation of the spin rate to parallelize three assay protocols in a sample-to-answer fashion; in addition, we demonstrate flexibility of application without redesigning of the cartridge towards variants of the common Enzyme-Linked Immuno-Sorbent Assay (ELISA) format. As a pilot application, we further implement liquid handling automation for the detection of two distinct PCa markers, free PSA and human epidermal growth factor receptor-type 2, (HER2), using two types of ELISA i.e. sandwich and competitive, respectively. (C) 2018 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available